{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:00:33Z","timestamp":1790935233558,"version":"4.1.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.clinthera.2012.02.002","type":"journal-article","created":{"date-parts":[[2012,3,19]],"date-time":"2012-03-19T13:21:19Z","timestamp":1332163279000},"page":"521-536","source":"Crossref","is-referenced-by-count":114,"title":["Role of RANK Ligand and Denosumab, a Targeted RANK Ligand Inhibitor, in Bone Health and Osteoporosis: A Review of Preclinical and Clinical Data"],"prefix":"10.1016","volume":"34","author":[{"given":"David W.","family":"Dempster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl L.","family":"Lambing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Kostenuik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Grauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2012.02.002_bib1","first-page":"11","article-title":"Anatomy and functions of the adult skeleton","volume":"7","author":"Dempster","year":"2006"},{"key":"10.1016\/j.clinthera.2012.02.002_bib2","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1359\/jbmr.0070614","article-title":"Skeletal self-repair: stress fracture healing by rapid formation and densification of woven bone","volume":"22","author":"Uthgenannt","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2012.02.002_bib3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/BF02058664","article-title":"Tetracycline-based histological analysis of bone remodeling","volume":"3","author":"Frost","year":"1969","journal-title":"Calcif Tissue Res"},{"key":"10.1016\/j.clinthera.2012.02.002_bib4","first-page":"359","article-title":"Evidence that bone resorption precedes formation at the cellular level","volume":"12","author":"Takahashi","year":"1964","journal-title":"Henry Ford Hosp Med Bull"},{"key":"10.1016\/j.clinthera.2012.02.002_bib5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF02409438","article-title":"Mean wall thickness and formation periods of trabecular bone packets in idiopathic osteoporosis","volume":"33","author":"Darby","year":"1981","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.clinthera.2012.02.002_bib6","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1172\/JCI111096","article-title":"Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis","volume":"72","author":"Parfitt","year":"1983","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2012.02.002_bib7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1210\/edrv-7-4-379","article-title":"Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease","volume":"7","author":"Eriksen","year":"1986","journal-title":"Endocr Rev"},{"key":"10.1016\/j.clinthera.2012.02.002_bib8","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00198-007-0542-6","article-title":"The remodeling transient and the calcium economy","volume":"19","author":"Aloia","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2012.02.002_bib9","first-page":"273","article-title":"Morphological basis of bone mineral measurements transient and steady state effects of treatment in osteoporosis","volume":"4","author":"Parfitt","year":"1980","journal-title":"Miner Electrolyte Metab"},{"key":"10.1016\/j.clinthera.2012.02.002_bib10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00198-007-0509-7","article-title":"Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease","volume":"19","author":"Yuan","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2012.02.002_bib11","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1359\/JBMR.040710","article-title":"Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients","volume":"19","author":"Recker","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2012.02.002_bib12","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1172\/JCI200317215","article-title":"Role of RANK ligand in mediating increased bone resorption in early postmenopausal women","volume":"111","author":"Eghbali-Fatourechi","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2012.02.002_bib13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.clinthera.2012.02.002_bib14","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1210\/en.139.3.1329","article-title":"Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG\/OCIF inhibits osteoclastogenesis in vitro","volume":"139","author":"Yasuda","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.clinthera.2012.02.002_bib15","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.clinthera.2012.02.002_bib16","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1073\/pnas.96.7.3540","article-title":"Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand","volume":"96","author":"Hsu","year":"1999","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.clinthera.2012.02.002_bib17","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0002-9440(10)64556-7","article-title":"Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo","volume":"157","author":"Lacey","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clinthera.2012.02.002_bib18","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1083\/jcb.145.3.527","article-title":"The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts","volume":"145","author":"Burgess","year":"1999","journal-title":"J Cell Biol"},{"key":"10.1016\/j.clinthera.2012.02.002_bib19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.clinthera.2012.02.002_bib20","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1210\/en.140.9.4367","article-title":"Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells","volume":"140","author":"Hofbauer","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.clinthera.2012.02.002_bib21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0006-291X(02)00667-8","article-title":"Isoflavones regulate interleukin-6 and osteoprotegerin synthesis during osteoblast cell differentiation via an estrogen-receptor-dependent pathway","volume":"295","author":"Chen","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clinthera.2012.02.002_bib22","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S8756-3282(02)00953-5","article-title":"The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts","volume":"32","author":"Bord","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2012.02.002_bib23","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1532-5415.1960.tb00135.x","article-title":"Osteoporosis: a hard look","volume":"8","author":"Frost","year":"1960","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.clinthera.2012.02.002_bib24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0021-9290(82)80001-8","article-title":"A hypothetical mechanism for the stimulation of osteonal remodelling by fatigue damage","volume":"15","author":"Martin","year":"1982","journal-title":"J Biomech"},{"key":"10.1016\/j.clinthera.2012.02.002_bib25","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S8756-3282(02)00815-3","article-title":"The contribution of the organic matrix to bone's material properties","volume":"31","author":"Burr","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2012.02.002_bib26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S8756-3282(98)00104-5","article-title":"Intracortical remodeling in adult rat long bones after fatigue loading","volume":"23","author":"Bentolila","year":"1998","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2012.02.002_bib27","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/jor.20395","article-title":"Effect of short-term treatment with alendronate on ulnar bone adaptation to cyclic fatigue loading in rats","volume":"25","author":"Barrett","year":"2007","journal-title":"J Orthop Res"},{"key":"10.1016\/j.clinthera.2012.02.002_bib28","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S8756-3282(98)00103-3","article-title":"Influence of microdamage on fracture toughness of the human femur and tibia","volume":"23","author":"Norman","year":"1998","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2012.02.002_bib29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12018-008-9015-5","article-title":"Skeletal microdamage: less about biomechanics and more about remodeling","volume":"6","author":"Allen","year":"2008","journal-title":"Clin Rev Bone Miner Metab"},{"key":"10.1016\/j.clinthera.2012.02.002_bib30","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1359\/jbmr.2001.16.2.348","article-title":"The effect of a single dose of osteoprotegerin in postmenopausal women","volume":"16","author":"Bekker","year":"2001","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2012.02.002_bib31","series-title":"Prolia (denosumab)","year":"2010"},{"key":"10.1016\/j.clinthera.2012.02.002_bib32","series-title":"European Public Assessment Report","year":"2010"},{"key":"10.1016\/j.clinthera.2012.02.002_bib33","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1210\/er.2007-0014","article-title":"Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease","volume":"29","author":"Kearns","year":"2008","journal-title":"Endocr Rev"},{"key":"10.1016\/j.clinthera.2012.02.002_bib34","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes Dev"},{"key":"10.1016\/j.clinthera.2012.02.002_bib35","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1006\/bbrc.1998.8697","article-title":"Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor\/osteoprotegerin","volume":"247","author":"Mizuno","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clinthera.2012.02.002_bib36","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1359\/jbmr.090215","article-title":"One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strength","volume":"24","author":"Ominsky","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2012.02.002_bib37","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2012.02.002_bib38","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00223-008-9133-6","article-title":"Soluble RANKL induces high bone turnover and decreases bone volume, density, and strength in mice","volume":"82","author":"Lloyd","year":"2008","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.clinthera.2012.02.002_bib39","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1359\/jbmr.081112","article-title":"Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine\/human) RANKL","volume":"24","author":"Kostenuik","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2012.02.002_bib40","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/ng2076","article-title":"Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL","volume":"39","author":"Sobacchi","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.clinthera.2012.02.002_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-010-1272-8","article-title":"New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK\/RANKL axis","volume":"22","author":"Crockett","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2012.02.002_bib42","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1006\/bbrc.1998.9788","article-title":"RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis","volume":"253","author":"Nakagawa","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clinthera.2012.02.002_bib43","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1101\/gad.13.18.2412","article-title":"RANK is essential for osteoclast and lymph node development","volume":"13","author":"Dougall","year":"1999","journal-title":"Genes Dev"},{"key":"10.1016\/j.clinthera.2012.02.002_bib44","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1073\/pnas.97.4.1566","article-title":"RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism","volume":"97","author":"Li","year":"2000","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.clinthera.2012.02.002_bib45","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ctrv.2007.09.002","article-title":"RANK ligand as a therapeutic target for bone metastases and multiple myeloma","volume":"34","author":"Roodman","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clinthera.2012.02.002_bib46","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.coph.2005.06.005","article-title":"Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength","volume":"5","author":"Kostenuik","year":"2005","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.02.002_bib47","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1359\/jbmr.080109","article-title":"RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats","volume":"23","author":"Ominsky","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2012.02.002_bib48","doi-asserted-by":"crossref","first-page":"28164","DOI":"10.1074\/jbc.M110.101964","article-title":"Are osteoclasts needed for the bone anabolic response to parathyroid hormone?","volume":"285","author":"Pierroz","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2012.02.002_bib49","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bone.2011.04.001","article-title":"Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys","volume":"49","author":"Ominsky","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2012.02.002_bib50","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bone.2011.03.769","article-title":"Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody","volume":"49","author":"Kostenuik","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2012.02.002_bib51","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1359\/jbmr.2000.15.6.1085","article-title":"Androgen deficiency induces high turnover osteopenia in aged male rats: a sequential histomorphometric study","volume":"15","author":"Erben","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2012.02.002_bib52","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1359\/jbmr.2002.17.11.2080","article-title":"Evidence from the aged orchidectomized male rat model that 17beta-estradiol is a more effective bone-sparing and anabolic agent than 5alpha-dihydrotestosterone","volume":"17","author":"Vandenput","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2012.02.002_bib53","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2009.05.024","article-title":"Orchiectomy upregulates free soluble RANKL in bone marrow of aged rats","volume":"45","author":"Proell","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2012.02.002_bib54","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.bone.2009.06.011","article-title":"Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin","volume":"45","author":"Li","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2012.02.002_bib55","doi-asserted-by":"crossref","first-page":"9416","DOI":"10.1073\/pnas.1533500100","article-title":"Suppressive function of androgen receptor in bone resorption","volume":"100","author":"Kawano","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2012.02.002_bib56","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00198-007-0452-7","article-title":"Estradiol rapidly inhibits osteoclastogenesis and RANKL expression in bone marrow cultures in postmenopausal women: a pilot study","volume":"19","author":"Taxel","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2012.02.002_bib57","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/36593","article-title":"A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function","volume":"390","author":"Anderson","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2012.02.002_bib58","doi-asserted-by":"crossref","first-page":"30202","DOI":"10.1074\/jbc.M403968200","article-title":"A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response","volume":"279","author":"Seshasayee","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2012.02.002_bib59","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.clim.2003.09.001","article-title":"Regulatory effects of osteoprotegerin on cellular and humoral immune responses","volume":"109","author":"Stolina","year":"2003","journal-title":"Clin Immunol"},{"key":"10.1016\/j.clinthera.2012.02.002_bib60","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.4049\/jimmunol.166.3.1482","article-title":"Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function","volume":"166","author":"Yun","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.clinthera.2012.02.002_bib61","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00198-010-1326-y","article-title":"Do RANKL inhibitors (denosumab) affect inflammation and immunity?","volume":"22","author":"Ferrari-Lacraz","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2012.02.002_bib62","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1084\/jem.189.7.1025","article-title":"TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation","volume":"189","author":"Bachmann","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.clinthera.2012.02.002_bib63","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S1074-7613(03)00326-1","article-title":"Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin","volume":"19","author":"Ashcroft","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.clinthera.2012.02.002_bib64","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2165\/11594240-000000000-00000","article-title":"Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis","volume":"50","author":"Sutjandra","year":"2011","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2012.02.002_bib65","first-page":"S190","article-title":"Denosumab an inhibitor of RANKL has pharmacokinetics similiar to other monoclonal antibodies","volume":"21","author":"Jang","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2012.02.002_bib66","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2012.02.002_bib67","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2012.02.002_bib68","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2012.02.002_bib69","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2012.02.002_bib70","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.02.002_bib71","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/jbmr.251","article-title":"Effects of denosumab on bone turnover markers in postmenopausal osteoporosis","volume":"26","author":"Eastell","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2012.02.002_bib72","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2012.02.002_bib73","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jocd.2008.04.001","article-title":"Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate","volume":"11","author":"Beck","year":"2008","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.clinthera.2012.02.002_bib74","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bone.2010.04.594","article-title":"Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density","volume":"47","author":"Genant","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2012.02.002_bib75","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1002\/jbmr.81","article-title":"Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate","volume":"25","author":"Seeman","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2012.02.002_bib76","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/jbmr.149","article-title":"Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies","volume":"25","author":"Reid","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2012.02.002_bib77","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1210\/jc.2010-2784","article-title":"Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk","volume":"96","author":"Boonen","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2012.02.002_bib78","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2012.02.002_bib79","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00198-011-1755-2","article-title":"Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?","volume":"23","author":"Watts","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2012.02.002_bib80","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/jbmr.403","article-title":"Effects of denosumab on fracture and bone mineral density by level of kidney function","volume":"26","author":"Jamal","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2012.02.002_bib81","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/jbmr.1479","article-title":"Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension","volume":"27","author":"Papapoulos","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2012.02.002_bib82","first-page":"S20","article-title":"Effects on denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial","volume":"24","author":"McClung","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2012.02.002_bib83","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/11207100-000000000-00000","article-title":"Spotlight on denosumab in postmenopausal osteoporosis","volume":"25","author":"Moen","year":"2011","journal-title":"BioDrugs"},{"key":"10.1016\/j.clinthera.2012.02.002_bib84","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.maturitas.2010.02.008","article-title":"Treatment of osteoporosis with denosumab","volume":"66","author":"Lewiecki","year":"2010","journal-title":"Maturitas"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181200080X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181200080X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,24]],"date-time":"2018-11-24T22:57:12Z","timestamp":1543100232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929181200080X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":84,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S014929181200080X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.02.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}